SAGE Therapeutics (SAGE) Reports Q2 Loss of $0.36
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Stifel Transfers Sage Therapeutics (SAGE), Maintains Buy
August 6, 2018 4:16 PM EDTStifel assumes coverage on Sage Therapeutics (NASDAQ: SAGE) with a Buy rating and a price target of $239.00.
Analyst Paul Matteis assumes coverage, maintains Buy and raises the PT to $239.00 (from $198.00)
For an analyst ratings summary and ratings history on Sage Therapeutics... More
Piper Jaffray Starts Sage Therapeutics (SAGE ) at Overweight
August 6, 2018 5:34 AM EDTPiper Jaffray initiates coverage on Sage Therapeutics (NASDAQ: SAGE ) with a Overweight rating and a price target of $206.00.
Analyst Danielle Brill believes the company is attractive citing robust supportive data generated in 2018, the novel approach to threat of CNS disorders, the pipeline depth, and consistent management... More
